Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

Earnings live: Salesforce stock rises on upbeat guidance, Snowflake tumbles, American Eagle surges

View original at finance.yahoo.com
Earnings live: Salesforce stock rises on upbeat guidance, Snowflake tumbles, American Eagle surges The third quarter earnings season is winding down, and only a handful of major companies have yet to report results…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • All consumers are seeking value, marrying value-seeking behavior with convenience and discovery is where Dollar Tree thrives

    80% confidence
  • Q2 results are strongest in Credo's history, reflecting continued build-out of world's largest AI training and inference clusters. AI clusters now measured in hundreds of thousands of GPUs, soon millions.

    80% confidence
  • Achieved three years of consecutive quarterly sales growth with record Q3 net sales up 7%. Hollister grew 16% on strong back-to-school and fall transition. Abercrombie made sequential progress, aiming for Q4 brand sales approximately flat to last year's record.

    80% confidence
  • Strong momentum driven by all-around competitiveness of NIO, ONVO, and FIREFLY brand offerings. Expect Q4 deliveries of 120,000-125,000 units, up 65.1%-72.0% YoY, setting new quarterly record.

    80% confidence
  • Street is underestimating growth potential for CrowdStrike as second/third derivative beneficiary of AI Revolution. CrowdStrike is AI-powered cybersecurity businesses increasingly can't live without.

    80% confidence
  • Q3 was exceptional quarter. Existing customers expanding and net-new customer additions continue showing strength. Companies choosing MongoDB for unified data platform powering mission-critical workloads and AI platform shift.

    80% confidence
  • Analysts expected 7.9% jump in earnings per share in Q3 as of Sept. 30

    80% confidence
  • S&P 500 companies with earnings beats saw stock price increase average 0.4% in four-day period around earnings release, less than five-year average of 0.9%

    80% confidence
  • 83% of S&P 500 earnings surprises were to the upside in Q3 2025

    80% confidence
  • 3 million more households are now part of Dollar Tree customer base compared to last year, with high-income consumers (>$100k/year) making up majority of new customers

    80% confidence
  • Enterprises want AI that can work within secure, trusted data environments without compromise. Partnership brings Claude directly into Snowflake where data already lives.

    80% confidence
  • 95% of S&P 500 companies have reported Q3 earnings as of Nov. 21, and analysts expect 13.4% jump in earnings per share during third quarter

    80% confidence
  • Strong momentum continued into Q4 with record-breaking Thanksgiving weekend led by acceleration in demand across brands and channels

    80% confidence
  • If 13.4% earnings growth holds, it would mark fourth straight quarter of double-digit earnings growth and acceleration from 12% in Q2

    80% confidence
  • Companies reporting earnings below expectations saw stock decrease 5% on average, well below five-year average decrease of 2.6%

    80% confidence
  • Celestial AI acquisition further strengthens Marvell's position at forefront of fastest-growing opportunities in AI datacenter infrastructure

    80% confidence
  • Q3 sales were strongest in 13 quarters, reflecting acceleration of Bold New Chapter strategy and demonstrating enterprise-wide changes are resonating with customers

    80% confidence

Data points we hold from this source

Salesforce · revenue10.27 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Earnings live: Salesforce stock rises on upbeat guidance, Snowflake tumbles, American Eagle surges — Source | Via News | ViaNews EU